RYTM stock forecast
Our latest prediction for Rhythm Pharmaceuticals, Inc.'s stock price was made on the March 18, 2019 when the stock price was at 30.27$.
In the short term (2weeks), RYTM's stock price should outperform the market by 0.21%. During that period the price should oscillate between -7.51% and +9.55%.
In the medium term (3months), RYTM's stock price should outperform the market by 3.22%. During that period the price should oscillate between -16.05% and +28.27%.Get email alerts
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.39$ per share.
The book value per share is 8.32$
Three months stock forecastMarch 18, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|